Dahong Yu Selected Research

Dahong Yu Research Topics

5	Type 2 Diabetes Mellitus (MODY) 01/2022 - 08/2006
3	Insulin Resistance 01/2010 - 08/2006
2	Ulcerative Colitis 01/2017 - 01/2016
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2010 - 12/2006
2	Obesity 01/2010 - 08/2006
1	Vitiligo 01/2023
1	Carcinoma (Carcinomatosis) 01/2023
1	Coronary Disease (Coronary Heart Disease) 01/2022
1	Psoriasis (Pustulosis Palmaris et Plantaris) 12/2020
1	Herpes Zoster 01/2017
1	Infections 01/2017
1	Skin Neoplasms (Skin Cancer) 01/2017
1	Pain (Aches) 08/2011
1	Opioid-Induced Constipation 08/2011
1	Weight Gain 01/2010
1	Hypoglycemia (Reactive Hypoglycemia) 06/2007
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 08/2006
1	Short Bowel Syndrome 07/2002

4	Rosiglitazone (Avandia)FDA Link 01/2010 - 12/2006
3	C-Reactive ProteinIBA 01/2010 - 08/2006
2	tofacitinibIBA 01/2017 - 01/2016
2	Glucose (Dextrose)FDA LinkGeneric 12/2006 - 08/2006
1	Janus KinasesIBA 01/2023
1	Tec protein-tyrosine kinaseIBA 01/2023
1	Sirtuin 1IBA 01/2022
1	PF-06700841IBA 12/2020
1	Janus Kinase InhibitorsIBA 01/2017
1	Tumor Necrosis Factor InhibitorsIBA 01/2017
1	LipidsIBA 01/2017
1	Leukocyte L1 Antigen Complex (Calgranulin)IBA 01/2016
1	methylnaltrexone FDA Link 08/2011
1	mu Opioid Receptors (mu Opioid Receptor)IBA 08/2011
1	Glyburide (Glibenclamide)FDA LinkGeneric 01/2010
1	Metformin (Glucophage)FDA LinkGeneric 01/2010
1	Insulin (Novolin)FDA Link 06/2007
1	LDL Lipoproteins (beta Lipoproteins)IBA 12/2006
1	oxidized low density lipoproteinIBA 12/2006
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 12/2006
1	Fibrinogen (Factor I)FDA Link 08/2006
1	AntigensIBA 08/2006
1	CholesterolIBA 08/2006
1	Sodium-Glucose Transport ProteinsIBA 07/2002

3	Therapeutics 01/2017 - 12/2006
1	Glycemic Control 06/2007